In Vitro Evaluation of Antibacterial and Antifungal Properties of Some New 1, 3, 4-Oxadiazole Derivatives Containing Phenyl Group

Document Type : Original Research

Authors
N. Zarrabi 1
A. souldozi 2
Y. SarveAhrabi 1
1 Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran
2 Department of Chemistry, Urmia Branch, Islamic Azad University, Urmia, Iran
10.29252/iem.6.3.177
Abstract




Aims: Antibiotic resistance is recognized as one of the most challenging public health problems in the world. The need for new antibacterial and antifungal drugs is justified because many pathogens are currently resistant to available drugs. Several components of 1, 3, 4‑oxadiazoles have been shown to pose a wide range of antibacterial activities.

Materials & Methods: The new derivatives of 1, 3, 4-oxadiazole were synthesized using a single-stage method. The structure of derivatives was evaluated by IR, H-NMR, C-NMR, and GC-Mass methods. Then to measure the antibacterial and antifungal activities of the prepared derivatives at a concentration of 0.5 mg/mL, agar well diffusion method was employed, and the minimum inhibitory concentration (MIC) and the minimum bactericidal/fungicidal concentration (MBC/MFC) were determined with three replications.

Findings: The study of antibacterial properties of the prepared derivatives showed the highest activity of the compounds 4b-g against Enterococcus faecalis strains, among which the compound 4g with IZ= 55.66 ± 0.5 mm and MIC=31.25 mg/mL had the greatest effect compared to the others. Also, the compound 4f with MIC= 125 mg/mL had a powerful effect against E. faecalis strains. In the case of fungal samples, the highest activity of the compound 4b was with IZ=12.33±0.5 mm against Candida glabrata and with IZ=13.33±0.5 mm against C. krusei strains.

Conclusion: The new 1, 3, 4‑oxadiazole derivatives (4b, 4d, and 4g) with tolyl, dimetylphenyl, and methoxyphenyl groups were shown to be a promising compounds for pharmaceutical applications so that by adding other functional groups to their structure, it is possible to increase the destructive power of these compounds.

Keywords

Subjects

1. White NJ. Antimalarial drug resistance. The Journal of clinical investigation. 2004 Apr 15;113(8):1084-92.
2. Antony HA, Parija SC. Antimalarial drug resistance: an overview. Tropical parasitology. 2016 Jan;6(1):30.
3. Lemos JA, Palmer SR, Zeng L, Wen ZT, Kajfasz JK, Freires IA, Abranches J, Brady LJ. The biology of Streptococcus mutans. Gram‐Positive Pathogens. 2019 Oct 1:435-48.
4. Jafri H, Khan MS, Ahmad I. In vitro efficacy of eugenol in inhibiting single and mixed-biofilms of drug-resistant strains of Candida albicans and Streptococcus mutans. Phytomedicine. 2019 Feb 15;54:206-13.
5. Dahl A, Iversen K, Tonder N, Hoest N, Arpi M, Dalsgaard M, Chehri M, Soerensen LL, Fanoe S, Junge S, Hoest U. Prevalence of infective endocarditis in Enterococcus faecalis bacteremia. Journal of the American College of Cardiology. 2019 Jul 16;74(2):193-201.
6. Davis, E., Hicks, L., Ali, I., Salzman, E., Wang, J., Snitkin, E., Gibson, K., Cassone, M., Mody, L. and Foxman, B., 2020, January. Epidemiology of Vancomycin-Resistant Enterococcus faecium and Enterococcus faecalis Colonization in Nursing Facilities. In Open forum infectious diseases (Vol. 7, No. 1, p. ofz553). US: Oxford University Press.
7. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Darling TN, Burton-Akright J, Bagheri M, Dombi E, Gruber A, Jarosinski PF, Martin S, Nathan N. Pharmacodynamic study of miransertib in individuals with Proteus syndrome. The American Journal of Human Genetics. 2019 Mar 7;104(3):484-91.
8. Bontron, S., Poirel, L., Kieffer, N., Savov, E., Trifonova, A., Todorova, I., Kueffer, G. and Nordmann, P., 2019. Increased Resistance to Carbapenems in Proteus mirabilis Mediated by Amplification of the bla VIM-1-Carrying and IS 26-Associated Class 1 Integron. Microbial Drug Resistance, 25(5), pp.663-667.
9. Caugant DA, Brynildsrud OB. Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis. Nature Reviews Microbiology. 2019 Nov 8:1-3.
10. McNamara LA, Potts C, Blain AE, Retchless AC, Reese N, Swint S, Lonsway D, Karlsson M, Lunquest K, Sweitzer JJ, Wang X. Detection of Ciprofloxacin-Resistant, β-Lactamase–Producing Neisseria meningitidis Serogroup Y Isolates—United States, 2019–2020. Morbidity and Mortality Weekly Report. 2020 Jun 19;69(24):735.
11. Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, Sobel JD, Herbrecht R, Rahav G, Jaruratanasirikul S, Chetchotisakd P. Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial. Clinical Infectious Diseases. 2019 May 30;68(12):1981-9.
12. Yeh SJ, Yeh CC, Lan CY, Chen BS. Investigating Common Pathogenic Mechanisms between Homo sapiens and Different Strains of Candida albicans for Drug Design: Systems Biology Approach via Two-Sided NGS Data Identification. Toxins. 2019 Feb;11(2):119.
13. Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clinical Microbiology and Infection. 2019 Jul 1;25(7):792-8.
14. Sarveahrabi Y, Souldozi A, Talebi R. 2-Substituent Synthesis of 5-3-Methoxyphenyl and 5-4-Methoxyphenyl-1, 3, 4-Oxadiazoles, 2-Yl-Pyridine-2-Yl-Methanol in Positions of 2 and 3 of 1, 3, 4-Oxadiazoles Containing Halogen and the Evaluation of Their Antibacterial Properties. Navid No. 2020;22(72):1-3.
15. Bitla S, Sagurthi SR, Dhanavath R, Reddy PM, Birudaraju S, Gayatri AA, Kumar BV, Atcha KR. Design and synthesis of triazole conjugated novel 2, 5-diaryl substituted 1, 3, 4-oxadiazoles as potential antimicrobial and anti-fungal agents. Journal of Molecular Structure. 2020 Jun 20:128705.
16. Maslat AO, Abussaud M, Tashtoush H, AL-Talib M. Synthesis, antibacterial, antifungal and genotoxic activity of bis-1, 3, 4-oxadiazole derivatives. Polish journal of pharmacology. 2002 Jan 1;54(1):55-60..
17. Ahsan MJ, Choupra A, Sharma RK, Jadav SS, Padmaja P, Hassan M, Al-Tamimi A, Geesi MH, Bakht MA. Rationale design, synthesis, cytotoxicity evaluation, and molecular docking studies of 1, 3, 4-oxadiazole analogues. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2018 Jan 1;18(1):121-38.
18- Bhaumik A, Eswaraiah MC, Chakraborty R. Evaluation of Antimicrobial Profile of Some Novel 1, 3, 4-Oxadiazole Derivatives Followed by Molecular Docking Against 3G7E Bacterial DNA Gyrase. Journal of Drug Delivery and Therapeutics. 2019 Jul 15;9(4):438-53.
19. SarveAhrabi Y, Souldozi A, Zarrabi Ahrabi N. In Vitro Evaluation of Antimicrobial Properties of Some New 1, 3, 4-Oxadiazole Derivatives against Acinetobacter baumannii. Infection Epidemiology and Microbiology. 2020 Feb 10;6(1):37-49.
20. Rohand T, Ramli Y, Baruah M, Budka J, Das AM. Synthesis, structure elucidation and antimicrobial properties of new bis-1, 3, 4-oxadiazole derivatives. Pharmaceutical Chemistry Journal. 2019 May 5;53(2):150-4.
21. Shi J, Luo N, Ding M, Bao X. Synthesis, in vitro antibacterial and antifungal evaluation of novel 1, 3, 4-oxadiazole thioether derivatives bearing the 6-fluoroquinazolinylpiperidinyl moiety. Chinese Chemical Letters. 2020 Feb 1;31(2):434-8.
22. Souldozi A, Karami S. One-pot three-component reaction for the synthesis of novel series of fully substituted 1, 3, 4-oxadiazole derivatives bearing pyridine moiety. Phosphorus, Sulfur, and Silicon and the Related Elements. 2016 Jun 2;191(6):867-70.
23. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. 2017.
24. Lee WB, Fu CY, Chang WH, You HL, Wang CH, Lee MS, Lee GB. A microfluidic device for antimicrobial susceptibility testing based on a broth dilution method. Biosensors and Bioelectronics. 2017 Jan 15;87:669-78.
25. Lushniak BD. Antibiotic resistance: a public health crisis. Public Health Reports. 2014 Jul;129(4):314-6.
26. Othman AA, Kihel M, Amara S. 1, 3, 4-Oxadiazole, 1, 3, 4-thiadiazole and 1, 2, 4-triazole derivatives as potential antibacterial agents. Arabian Journal of Chemistry. 2019 Nov 1;12(7):1660-75.
27. Aghekyan АА, Mkryan GG, Panosyan HA, Safaryan AS, Stepanyan HM. Synthesis and Antibacterial Activity of Novel (4-Methoxyphenyl)-tetrahydropyranyl-substituted 1, 3, 4-Oxadiazoles. Russian Journal of Organic Chemistry. 2020 Feb;56:281-6.
28. Guo Y, Xu T, Bao C, Liu Z, Fan J, Yang R, Qin S. Design and synthesis of new norfloxacin-1, 3, 4-oxadiazole hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA). European Journal of Pharmaceutical Sciences. 2019 Aug 1;136:104966.
29. Bhaumik A, Eswaraiah MC, Chakraborty R. Evaluation of Antimicrobial Profile of Some Novel 1, 3, 4-Oxadiazole Derivatives Followed by Molecular Docking Against 3G7E Bacterial DNA Gyrase. Journal of Drug Delivery and Therapeutics. 2019 Jul 15;9(4):438-53.
30. Tresse C, Radigue R, Von Borowski RG, Thepaut M, Le HH, Demay F, Georgeault S, Dhalluin A, Trautwetter A, Ermel G, Blanco C. Synthesis and evaluation of 1, 3, 4-oxadiazole derivatives for development as broad-spectrum antibiotics. Bioorganic & medicinal chemistry. 2019 Nov 1;27(21):115097.
Infection Epidemiology and Microbiology
Volume 6, Issue 3
August 2020
Pages 177-192